DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for inflammatory breast carcinoma — screening already-approved drugs against its 17-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInflammatory breast carcinoma maps to a 17-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for inflammatory breast carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tubulin alpha 1b (TUBA1B) — TUBA1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6S8L · 1.801 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
What the evidence adds up to
Inflammatory breast carcinoma is the most aggressive form of breast cancer, characterised by rapid proliferation and historically uniform fatality. A 2018 literature review states that multidisciplinary management has changed over the past three decades thanks to advances in medical treatments, though locoregional treatments including surgery and radiotherapy are still used in localised stages. The review notes that molecular profiling of the disease allows orientation towards new targeted therapeutic strategies with an impact on survival, but provides no concrete survival or response numbers.
A 2006 review describes inflammatory breast cancer as rare, aggressive, and lethal. It reports that management has evolved substantially over the last 40 years, with current multimodality therapy combining chemotherapy, surgery, and radiation. The review mentions that novel targeted therapies have recently become available and promise improved responses and survival, but again gives no specific response rates, survival figures, or sample sizes. A 1992 review repeats that the disease was uniformly fatal historically but that prognosis has improved with induction chemotherapy and coordinated multimodality treatment.
No abstract provides quantitative evidence of efficacy for any specific drug or regimen. The claims of improved survival and response are stated as promises or general observations, not backed by numbers from controlled trials. What is still missing are large, randomised trials with clearly reported endpoints, adequate funding for studies that can stratify patients by molecular profile, and any concrete data on how much survival or response has actually changed since the introduction of modern multimodality therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
World Journal of Oncology · 2018 · 49 citations · open access
Inflammatory Breast Cancer: A Literature Review
AbstractThe multidisciplinary management of inflammatory breast cancer (IBC), which is the most aggressive form of breast cancer due to its rapid proliferation, has changed over the past three decades thanks to advances in medical treatments that represent the basis of treatment, without eliminating the use of locoregional treatments including surgery and radiotherapy in the localized stages. The molecular profile determination of IBC allows the orientation towards new targeted therapeutic strategies with an impact on survival.
Systemic Treatments for Inflammatory Breast Cancer
AbstractInflammatory breast cancer is rare but represents the most aggressive and lethal form of locally advanced breast cancer. The management of inflammatory breast cancer has evolved substantially over the last 40 years; current multimodality therapy regimens combine chemotherapy, surgery, and radiation. While identification of the optimal combination of these traditional therapies remains a goal, novel targeted therapies that have recently become available promise improved responses and survival. In this review, we discuss some recent developments in the use of systemic therapies for inflammatory breast cancer.
Dialnet (Universidad de la Rioja) · 1992 · 0 citations
Ibn 'Arabî: entre la mística y la filosofía
AbstractInflammatory breast cancer is a rare but highly aggressive form of locally advanced breast cancer. Historically, this disease was uniformly fatal; however, with the advent of induction chemotherapy and carefully coordinated multimodality treatment, the prognosis of these patients has improved. This article reviews the clinical characteristics of inflammatory breast cancer and the recent advances in therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
